Conceivable Life Sciences is a biotech company revolutionizing fertility care by developing the world's first fully automated in vitro fertilization (IVF) laboratory. Their innovative approach integrates artificial intelligence (AI) and robotics to automate over 200 intricate steps involved in embryo creation, including delicate single-cell procedures like intracytoplasmic sperm injection (ICSI). Notably, they achieved the first fully automated ICSI, performed both onsite and remotely across a 3,000-mile distance between the reproductive cells and the embryologist operator in New York. ​

In January 2025, Conceivable secured an $18 million Series A financing round led by ARTIS Ventures, with participation from investors such as Atlantic Health Venture Studio, Muse Capital, and Scrub Capital, bringing their total funding to over $39 million. This capital supports a commercial pilot program, including a 100-patient Institutional Review Board (IRB) study currently underway, and preparations for a U.S. launch targeted for early 2026. ​

By automating the IVF process, Conceivable aims to enhance precision, quality, and scalability in fertility treatments, addressing the global demand for accessible and affordable reproductive care.